ATE223916T1 - Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung - Google Patents

Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung

Info

Publication number
ATE223916T1
ATE223916T1 AT95917497T AT95917497T ATE223916T1 AT E223916 T1 ATE223916 T1 AT E223916T1 AT 95917497 T AT95917497 T AT 95917497T AT 95917497 T AT95917497 T AT 95917497T AT E223916 T1 ATE223916 T1 AT E223916T1
Authority
AT
Austria
Prior art keywords
crystals
production
crystalline
lyophilized preparations
warming
Prior art date
Application number
AT95917497T
Other languages
English (en)
Inventor
Masayoshi Inoue
Kazuichi Fujikane
Kenji Sugiyama
Hideaki Tai
Fumihiko Matsubara
Katsuo Oda
Takashi Oya
Yoshinori Hamada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE223916T1 publication Critical patent/ATE223916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95917497T 1994-05-02 1995-04-28 Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung ATE223916T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9353794 1994-05-02
JP10855494 1994-05-23
PCT/JP1995/000858 WO1995029913A1 (fr) 1994-05-02 1995-04-28 Cristal de derive de pyrrolidylthiocarbapeneme, preparation lyophilisee le contenant et son procede de production

Publications (1)

Publication Number Publication Date
ATE223916T1 true ATE223916T1 (de) 2002-09-15

Family

ID=26434878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95917497T ATE223916T1 (de) 1994-05-02 1995-04-28 Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung

Country Status (11)

Country Link
US (1) US6111098A (de)
EP (1) EP0758651B1 (de)
KR (1) KR100314558B1 (de)
CN (1) CN1048248C (de)
AT (1) ATE223916T1 (de)
AU (1) AU700545B2 (de)
DE (1) DE69528166T2 (de)
ES (1) ES2183874T3 (de)
PT (1) PT758651E (de)
TW (1) TW387889B (de)
WO (1) WO1995029913A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010089886A (ko) * 1999-10-12 2001-10-12 도리이 신이찌로 경구 의약 조성물
BRPI0109712B8 (pt) 2000-03-31 2021-05-25 Shionogi & Co forma de cristal de derivado de pirroliditiocarbapenemo
JP5004355B2 (ja) * 2001-05-10 2012-08-22 塩野義製薬株式会社 アセチルチオピロリジン誘導体の製法
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
US20060121080A1 (en) * 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
TWI353855B (en) * 2005-05-26 2011-12-11 Shionogi & Co Method for preparing an aqueous solution of doripe
CN100582106C (zh) * 2006-01-27 2010-01-20 上海医药工业研究院 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体
WO2007142212A1 (ja) * 2006-06-08 2007-12-13 Dainippon Sumitomo Pharma Co., Ltd. 製剤組成物
CN101466713A (zh) * 2006-07-03 2009-06-24 成都地奥九泓制药厂 多尼培南的新结晶及其制备方法和用途
CN101333219B (zh) * 2007-06-26 2010-10-13 山东轩竹医药科技有限公司 含有巯基吡咯烷甲酰胺苯烷基杂环的培南衍生物
WO2009047604A1 (en) * 2007-10-08 2009-04-16 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of carbapenem antibiotic
US8445673B2 (en) * 2008-03-24 2013-05-21 Ranbaxy Laboratories Limited Process for the preparation of sterile doripenem
WO2010097686A1 (en) * 2009-02-26 2010-09-02 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of carbapenem antibiotic
US8691803B2 (en) * 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CN102285988B (zh) * 2011-09-08 2012-09-05 上海希迈医药科技有限公司 一种多尼培南水合物晶体及其制备方法
WO2013068910A1 (en) * 2011-11-08 2013-05-16 Ranbaxy Laboratories Limited Process for the preparation of polymorphs of doripenem
CA2874279C (en) 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
CN104072497B (zh) * 2013-03-29 2017-10-03 石药集团中奇制药技术（石家庄）有限公司 一种多尼培南新结晶及其制备方法
SG11201602256UA (en) 2013-09-24 2016-04-28 Meiji Seika Pharma Co Ltd Production method for diazabicyclooctane derivative and intermediary body thereof
SG11201602723RA (en) 2013-10-08 2016-05-30 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
WO2015167148A1 (ko) * 2014-04-28 2015-11-05 제이더블유중외제약 주식회사 도리페넴의 신규한 결정 및 이의 제조방법
TWI691499B (zh) * 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US4029655A (en) * 1975-04-11 1977-06-14 Eli Lilly And Company Method of preparing stable sterile crystalline cephalosporins for parenteral administration
JPS5294970A (en) * 1976-02-06 1977-08-10 Shimomura Seisakushiyo Kk Method of fixing parts
IL53427A0 (en) * 1976-11-24 1978-01-31 Lilly Co Eli Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
JPS6019759A (ja) * 1983-07-15 1985-01-31 Nippon Soda Co Ltd ホルムアミドオキシム誘導体その製造方法及び農園芸用殺菌剤
JPS6019758A (ja) * 1983-07-15 1985-01-31 Mitsui Toatsu Chem Inc ビウレツト構造を有するポリイソシアナ−トの製造方法
US4748238A (en) * 1984-03-14 1988-05-31 Merck & Co., Inc. Crystalline 1R,5S,6S,8R-1-methyl-2-(N,N-dimethylcarbamimidoylmethylthio)-6-(1-hydroxyethyl)-1-carbapen-2-em-3-carboxylic acid
JPS6143356A (ja) * 1984-08-07 1986-03-01 Nec Corp 共用フアイル管理装置
JPS61129123A (ja) * 1984-11-27 1986-06-17 Sankyo Co Ltd カルバペネム誘導体の安定な凍結乾燥製剤の製造法
JPS61172878A (ja) * 1985-01-28 1986-08-04 Sankyo Co Ltd カルバペネム誘導体の安定な凍結乾燥製剤の製法
JP2522671B2 (ja) * 1986-07-30 1996-08-07 住友製薬 株式会社 結晶態のカルバペネム化合物、その製造方法およびその化合物を含有する注射用抗菌剤
JPS63174927A (ja) * 1987-01-14 1988-07-19 Tanabe Seiyaku Co Ltd 抗菌性凍結乾燥製剤
PL157979B1 (pl) * 1989-02-14 1992-07-31 Sprezyna z dwoma stanami równowagi trwalej PL PL
JPH0459730A (ja) * 1990-06-26 1992-02-26 Dai Ichi Seiyaku Co Ltd セフェム系抗生物質含有凍結乾燥製剤
JPH0466202A (ja) * 1990-06-29 1992-03-02 Aichi Steel Works Ltd 溝形材の製造方法
JP2919112B2 (ja) * 1991-05-13 1999-07-12 武田薬品工業株式会社 セファロスポリン注射剤およびその製造法
US5317016A (en) * 1991-08-20 1994-05-31 Shionogi Seiyaku Kabushiki Kaisha Pyrrolidylthiocarbapenem derivative
TW264475B (de) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US5539102A (en) * 1992-02-21 1996-07-23 Shionogi Seiyaku Kabushiki Kaisha Production method for sulfamide

Also Published As

Publication number Publication date
AU700545B2 (en) 1999-01-07
EP0758651A4 (de) 1997-05-02
WO1995029913A1 (fr) 1995-11-09
TW387889B (en) 2000-04-21
DE69528166D1 (de) 2002-10-17
DE69528166T2 (de) 2003-04-30
AU2353395A (en) 1995-11-29
CN1151162A (zh) 1997-06-04
PT758651E (pt) 2002-12-31
CN1048248C (zh) 2000-01-12
ES2183874T3 (es) 2003-04-01
EP0758651B1 (de) 2002-09-11
EP0758651A1 (de) 1997-02-19
US6111098A (en) 2000-08-29
KR100314558B1 (ko) 2002-02-28

Similar Documents

Publication Publication Date Title
ATE223916T1 (de) Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung
CA2036876A1 (fr) Derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ508842A (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
ATE46696T1 (de) 1- und 1,1-disubstituierte, 6-substituierte, 2carbamimidoyl-1-carbadethiapen-2-em-3carbons|uren, verfahren zur herstellung und diese enthaltende antibiotische zusammensetzung.
GB2198135B (en) Derivatives of cyclohexane
AT384424B (de) Verfahren zur herstellung von neuen 3-hydroxy-2-oxo-pyrrolidinderivaten und ihren salzen
HU9300110D0 (en) Method for producing aryl-cycloalkyl derivatives and medical preparatives containing them as active substance
DE69331003T2 (de) Kristalle von derivaten von chinozon carbonsäure-hydraten
KR890003775A (ko) 결정성 세파드록실 모노하이드레이트의 제조방법
BR9301098A (pt) Processo integrado para produção de frutose cristalina
CA1101840A (en) Process for preparing cephalosporin compounds
ES2099114T3 (es) Derivados de tienotriazolodiacepina opticamente activos.
DE68912270D1 (de) Lyophilisiertes MDM enthaltende Zusammensetzung und Verfahren zu deren Herstellung.
FI103120B (fi) Menetelmä laktitolin kiteyttämiseksi
JPS6434927A (en) Method for asymmetric photochemical reaction
GB2072675A (en) Cephapirin salts
Kuznetsova The Production of HgCr sub 2 Se sub 4 Single Crystals by the Method of Growth From Solution in a Melt
ATE186730T1 (de) Herstellung von kristallen aus diester phosphat monokazium-salz
JPS6442489A (en) Method for crystallization and purification of 7-acylamidodeacetoxycephalosporanic acid
EP0212260A1 (de) Verfahren zur Herstellung eines stabilisierten Bacampicillin-6-beta-halopenicillansäuresalzes
TH54272A (th) วิธีการตกผลึกของผลึกของโมโนโซเดียมกลูตาเมท โมโนไฮเดรท
TH26135B (th) วิธีการตกผลึกของผลึกของโมโนโซเดียมกลูตาเมท โมโนไฮเดรท
CA2132417A1 (en) A crystalline modification of 2,4-dioxo-6-methyl-1, 2,3,4-tetrahydropyrimidine, a method for the preparation thereof and a medical preparation based on it
LV12664A (lv) Synthesis of 4-substituted 2-oxobutenic acid sodium salts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758651

Country of ref document: EP